Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

01-04-2010 | Uitgave 3/2010

Quality of Life Research 3/2010

Preference values associated with stage III colon cancer and adjuvant chemotherapy

Tijdschrift:
Quality of Life Research > Uitgave 3/2010
Auteurs:
Jennie H. Best, Louis P. Garrison, William Hollingworth, Scott D. Ramsey, David L. Veenstra

Abstract

Purpose

To elicit preference values for health states associated with Stage III colon cancer (CRC) and to explore the effect of neuropathy associated with current adjuvant treatment.

Methods

We used time trade-off (TTO) techniques to elicit preferences from 49 CRC patients and 49 community members. We elicited preferences for 7 health states: remission; adjuvant therapy with no, mild, moderate, and severe neuropathy; metastatic stable; and metastatic progressive disease. Mean TTO values were adjusted for the covariates age, education, and current health.

Results

Patients’ adjusted mean TTO value for remission was 0.83; adjuvant chemotherapy health states ranged from 0.48 to 0.61. Significant differences were observed for both patient and community groups between TTO for remission and all adjuvant health states (P < 0.001), and between adjuvant therapy with no neuropathy and metastatic health states (P ≤ 0.001). Across all health states, patients’ values were on average 0.12 higher than community members (P < 0.05).

Conclusions

The findings highlight the trade-offs between the disutility of adjuvant treatment, the higher utility of remission, and the severe utility loss during metastatic disease. The preference values obtained from this study will be useful for informing patients’ treatment decisions and payer cost-utility analyses of adjuvant treatment for colon cancer.

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Literatuur
Over dit artikel

Andere artikelen Uitgave 3/2010

Quality of Life Research 3/2010 Naar de uitgave